Objective To investigate the effect of pancreatic kininogenase enteric coated tablets combined with dapa-gliflozin in the treatment of diabetic nephropathy.Methods A total of eighty patients with diabetic nephropathy admit-ted to Qixia People's Hospital from January 2021 to June 2023 were selected as the study objects,and were divided into control group and study group by random number table method,with forty cases in each group.The study group received pancreatic kininogenase enteric coated tablets combined with dapagliflozin therapy,while the control group received only dapagliflozin therapy.Renal function indexes,blood glucose indexes,inflammation indexes and quality of life were compared between the two groups before and after treatment.Results Before treatment,there were no sig-nificant difference in renal function,blood glucose,inflammation index and quality of life score between two groups(all P>0.05).After treatment,serum creatinine,24 h urinary protein quantity,blood glucose and inflammation indexes were all decreased in two groups,and those of the study group were lower than the control group,and the differences were statistically significant(all P<0.05).The levels of blood albumin and scores of MOS Item Short From Health Sur-vey and Control Status Scale for Diabeties in two groups after treatment were higher than before treatment,and the val-ues in the study group were higher than those in the control group,the differences were statistically significant(all P<0.05).Conclusion Pancreatic kininogenase enteric coated tablets combined with dapagliflozin therapy can effectively improve the renal function and blood glucose related indexes of diabetic nephropathy patients,reduce inflammatory re-sponse,thereby improving the renal prognosis of patients and improving the quality of life of patients.
NETL
NSTL
万方数据
